Shares of CVS Health Corp (NYSE:CVS) ended Tuesday session in green amid volatile trading. The shares closed up +0.64 points or 0.71% at $90.56 with 4.20 million shares getting traded. Post opening the session at $90.17, the shares hit an intraday low of $90.06 and an intraday high of $90.83 and the price vacillated in this range throughout the day. The company has a market cap of $96.59 billion and the numbers of outstanding shares have been calculated to be 1.07 billion shares.
CVS Health Corp (CVS) on Sept. 22, 2016 announced that its board of directors has approved a quarterly dividend of $0.425 (42.5 cents) per share on the corporation’s common stock. The dividend is payable on November 3, 2016, to holders of record on October 24, 2016.
Shares of Nymox Pharmaceutical Corporation (NASDAQ:NYMX) ended Tuesday session in red amid volatile trading. The shares closed down -0.06 points or -1.77% at $3.33 with 172,305.00 shares getting traded. Post opening the session at $3.34, the shares hit an intraday low of $3.30 and an intraday high of $3.45 and the price vacillated in this range throughout the day. The company has a market cap of $156.43 million and the numbers of outstanding shares have been calculated to be 46.14 million shares.
On Aug. 29, 2016 Nymox Pharmaceutical Corporation (NYMX) lead drug fexapotide which has been in development for over a decade and which has been tested by expert clinical trial investigative teams in over 70 distinguished clinical trial centers throughout the US, has been found after 7 years of prospective placebo controlled double blind studies of treatment of 995 U.S. men with prostate enlargement to not only show clinically meaningful and durable relief of BPH symptoms, but also to show a major reduction in the incidence of prostate cancer, compared to placebo and compared to the known and expected normal incidence of the disease. This is in stark contrast to some conventional BPH treatments in routine clinical use which on the other hand increase prostate cancer risk, and which have many other well-known undesirable side effects such as retrograde ejaculation which is when men lose the ability to have normal orgasms.
The same clinical program conducted at the same highly regarded treatment centers under rigorous trial scrutiny and performed strictly at arms-length by top teams of clinical investigators across the country, has now also shown that the long-term blinded placebo crossover group study has resulted in an 82-95% reduction in the number of these patients who required surgery after they received crossover fexapotide in the trial, as compared to patients who did not receive fexapotide but instead received crossover conventional approved BPH treatments (p<.0001). The aim of the crossover study was to determine the clinical benefit fexapotide can provide to men who initially were double blind randomized to and received placebo, remained blinded as to their placebo treatment, and who subsequently required additional medical and/or surgical treatment. In this study long-term outcomes were determined in 391 patients who were given double blind placebo injections, which were followed by crossover to other treatments at the patients’ discretion. The numbers of blinded placebo patients who subsequently received surgical treatment during the next 2-3 years for their BPH symptoms were then prospectively analyzed.